Drug repositioning using in silico compound profiling

Future Medicinal Chemistry

Volumn 1, Issue 9, 2009, Pages 1723-1736

  Dubus, Elodie ^a   Ijjaali, Ismail ^a   Barberan, Olivier ^a   Petitet, Franois ^a  

^a Aureus Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; FINASTERIDE; METHADONE; RAPAMYCIN; SAQUINAVIR; SILDENAFIL; TELMISARTAN; THALIDOMIDE;

ARTICLE; COMPUTER MODEL; DRUG DESIGN; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; PHARMACOPHORE; PRIORITY JOURNAL;

BENZIMIDAZOLES; BENZOATES; DATABASES, FACTUAL; DRUG REPOSITIONING; METHADONE; RECEPTOR, MUSCARINIC M3; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROKININ-2; RECEPTORS, NEUROPEPTIDE; SAQUINAVIR; SIROLIMUS;

EID: 77953387346     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.123     Document Type: Article

References (60)

1. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int. J. Dermatol. 19(6), 318-322 (1980).
2. Teo SK, Stirling DI, Zeldis JB. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov. Today 10(2), 107-114 (2005).
3. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3(8), 673-683 (2004).
4. Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem. Biophys. Res. Commun. 334(3), 930-938 (2005).
5. Wharton J, Strange JW, Møller GM et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 172(1), 105-113 (2005).
6. Tsai BM, Turrentine MW, Sheridan BC et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann. Thorac. Surg. 81(1), 272-278 (2006).
7. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res. 101(11), 1084-1095 (2007).
8. Kirsch M, Kemp-Harper B, Weissmann N, Grimminger F, Schmidt HH. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. FASEB J. 22(1), 30-40 (2008).
9. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5(8), 689-702 (2006).
10. Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin. Pharmacother. 5(4), 933-940 (2004).
11. Harrison T, Samuel BU, Akompong T et al. Erythrocyte G protein-coupled receptor signaling in malarial infection. Science. 301(5640), 1734-1736 (2003).
12. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2(8), 415-416 (2006).
13. Plouffe D, Brinker A, McNamara C et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl Acad. Sci. USA 105(26), 9059-9064 (2008).
14. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br. J. Pharmacol. 152(1), 9-20 (2007).
15. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. Br. J. Pharmacol. 152(1), 21-37 (2007).
16. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat. Biotechnol. 24(7), 805-815 (2006).
17. Mestres J, Martín-Couce L, Gregori-Puigjane E, Cases M, Boyer S. Ligand-based approach to in silico pharmacology: nuclear receptor profiling. J. Chem. Inf. Model 46(6), 2725-2736 (2006).
18. Yildirim MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug-target network. Nat. Biotechnol. 25(10), 1119-1126 (2007).
19. Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK. Quantifying the relationships among drug classes. J. Chem. Inf. Model 48(4), 755-765 (2008).
20. Aronov AM, McClain B, Moody CS, Murcko MA. Kinase-likeness and kinaseprivileged fragments: toward virtual polypharmacology. J. Med. Chem. 51(5), 1214-1222 (2008).
21. Bisson WH, Cheltsov AV, Bruey-Sedano N et al. Discovery of anti-androgen activity of nonsteroidal scaffolds of marketed drugs. Proc. Natl Acad. Sci. USA 104(29), 11927-11932 (2007).
22. Martin RE, Green LG, Guba W, Kratochwil N, Christ A. Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach. J. Med. Chem. 50(25), 6291-6294 (2007).
23. Grau D, Serbedzija G. Innovative strategies for drug repurposing. Drug Discovery & Development. May 2005.
24. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25(2), 197-206 (2007).
25. Ebert B, Thorkildsen C andersen S, Christrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists. Biochem. Pharmacol. 56(5), 553-559 (1998).
26. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin. J. Pain. 16(Suppl. 2), S73-S79 (2000).
27. Lee AM, Jacoby DB, Fryer AD. Selective muscarinic receptor antagonists for airway diseases. Curr. Opin. Pharmacol. 1(3), 223-229 (2001).
28. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am. J. Med. 117(Suppl. 12A), S24-S32 (2004).
29. Williams JD. Non-antimicrobial activities of macrolides. Int. J. Antimicrob. Agents. 18(Suppl. 1), S89-S91 (2001).
30. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell. Mol. Biol. Lett. 10(3), 479-498 (2005).
31. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer. 94(2), 195-199 (2006).
32. Ghatta S, Tunstall RR, Kareem S, Rahman M, O'Rourke ST. Sirolimus causes relaxation of human vascular smooth muscle: a novel action of sirolimus mediated via ATP-sensitive potassium channels. J. Pharmacol. Exp. Ther. 320(3), 1204-1208 (2007).
33. Poitras P, Peeters TL. Motilin. Curr. Opin. Endocrinol. Diabetes Obes. 15(1), 54-57 (2008).
34. Van Vlem B, Schoonjans R, Vanholder R et al. In vitro evaluation of motilin agonism by macrolide immunosuppressive drugs. Nephrol. Dial. Transplant. 17(6), 973-977 (2002).
35. Takanashi H, Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul. Pept. 155(1-3), 18-23 (2009).
36. Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT. Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr. Med. Chem. 14(26), 2734-2748 (2007).
37. Patacchini R, Maggi CA. Peripheral tachykinin receptors as targets for new drugs. Eur. J. Pharmacol. 429(1-3), 13-21 (2001).
38. Doggrell SA. Telmisartan - killing two birds with one stone. Expert Opin. Pharmacother. 5(11), 2397-2400 (2004).
39. Kintscher U, Foryst-Ludwig A, Unger T. Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opin. Ther. Targets 12(10), 1257-1263 (2008).
40. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65, 261-311 (2003).
41. Nakaya K, Ayaori M, Hisada T et al. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARg. J. Atheroscler. Thromb. 14(3), 133-141 (2007).
42. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J. Biochem. 131(6), 773-779 (2002). (Pubitemid 34717579)
43. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Plateletactivating factor, a pleiotrophic mediator of physiological and pathological processes. Crit. Rev. Clin. Lab. Sci. 40(6), 643-672 (2003).
44. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet activating factor as a mediator and therapeutic approach in bronchial asthma. Inflammation 31(2), 112-120 (2008).
45. Bender A, Young DW, Jenkins JL et al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb. Chem. High Throughput Screen. 10(8), 719-731 (2007).
46. Kirchmair J, Distinto S, Schuster D, Spitzer G, Langer T, Wolber G. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. Curr. Med. Chem. 15(20), 2040-2053 (2008).
47. Mason JS, Migeon J, Dupuis P, Otto-Buc A. Use of broad biological profiling as relevant descriptor to describe and differentiate compounds: structure-in vitro (pharmacology-ADME)-in vivo (safety) relationships. In: Methods and Principles in Medicinal Chemistry: Antitargets (Volume 38). Vaz RJ, Klabunde T (Eds). Wiley-VCH Verlag GmbH & Co., Weinheim, Germany, 23-52 (2008).
48. Martin YC, Kofron JL, Traphagen LM. Do structurally similar molecules have similar biological activity? J. Med. Chem. 45(19), 4350-4358 (2002).
49. Nidhi, Glick M, Davies JW, Jenkins JL. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 46(3), 1124-1133 (2006).
50. Rognan D. Chemogenomic approaches to rational drug design. Br. J. Pharmacol. 152(1), 38-52 (2007).
51. Gregori-Puigjané E, Mestres J. A ligand-based approach to mining the chemogenomic space of drugs. Comb. Chem. High Throughput Screen. 11(8), 669-676 (2008).
52. Sato T, Matsuo Y, Honma T, Yokoyama S. In silico functional profiling of small molecules and its applications. J. Med. Chem. 51(24), 7705-7716 (2008).
53. Nettles JH, Jenkins JL, Bender A, Deng Z, Davies JW, Glick M. Bridging chemical and biological space: 'target fishing' using 2D and 3D molecular descriptors. J. Med. Chem. 49(23), 6802-6810 (2006).
54. Whitebread S, Hamon J, Bojanic D, Urban L. In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today. 10(21), 1421-1433 (2005).
55. Iyer M, Reschly EJ, Krasowski MD. Functional evolution of the pregnane X receptor. Expert. Opin. Drug Metab. Toxicol. 2(3), 381-397 (2006).
56. Thai KM, Ecker GF. Predictive models for HERG channel blockers: ligand-based and structure-based approaches. Curr. Med. Chem. 14(28), 3003-3026 (2007).
57. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 321(5886), 263-266 (2008).
58. Bender A, Scheiber J, Glick M et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem. 2(6), 861-873 (2007).
59. Scheiber J, Chen B, Milik M et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model. 49(2), 308-317 (2009).
60. Scheiber J, Jenkins JL, Sukuru SC et al. Mapping adverse drug reactions in chemical space. J. Med. Chem. 52(9), 3103-3107 (2009).